<DOC>
	<DOCNO>NCT01464671</DOCNO>
	<brief_summary>The objective study assess safety efficacy Angiomax® ( bivalirudin ) versus unfractionated heparin ( UFH ) patient present stable angina silent ischemia ( positive stress test without chest pain ) undergo percutaneous coronary intervention ( PCI ) . The primary endpoint study major minor bleeding event , define REPLACE-2 trial definition , index hospitalization 30 day post discharge .</brief_summary>
	<brief_title>Angiomax® Unfractionated Heparin Patients Undergoing Percutaneous Coronary Intervention</brief_title>
	<detailed_description>The purpose study compare randomize , control , single-blinded , 1:1 fashion UFH versus bivalirudin patient stable angina pectoris silent ischemia undergo PCI . Secondary study endpoint include : - Major adverse cardiac event ( MACE ) comprise cause mortality , myocardial infarction ( MI ) , ischemia driven target vessel revascularization ( TVR ) , cerebral vascular accident ( CVA ) . - Net adverse clinical event ( NACE ) consistent MACE plus major bleeding define REPLCE-2 criterion . - Cardiac death in-hospital 30 day post discharge . - MI in-hospital 30 day post discharge . - CVA in-hospital 30 day post discharge . - Incidence all-cause mortality 6 month 1 year . - MACE 6 month 1 year . - Incidence acute ( 0-24 hour post procedure ) stent thrombosis rate . - Incidence sub-acute ( 24 hour - 30 day ) stent thrombosis rate . - Length hospital stay ( LOS ) - Economic analysis ( total cost hospitalization ) 30 day post discharge .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Bivalirudin</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>1 . The patient male female ≥ 18 year age . 2 . The patient present stable angina pectoris , silent ischemia ( positive stress test without chest pain ) . 3 . The patient schedule coronary angiography , possible angioplasty . 4 . The patient able tolerate dual antiplatelet therapy aspirin clopidogrel minimum 30 day medication time PCI ( clopidogrel may administer PCI within 30 minute post PCI ) . 5 . The patient able willing conform requirement study voluntarily sign Informed Consent . 6 . The patient present form illness condition investigator 's opinion would impair result study . 7 . Women child bear potential must negative urine serum pregnancy test prior enrollment . 1 . Patients cardiogenic shock . 2 . Patients acute coronary syndrome , include unstable angina , nonSTelevation MI STEMI . 3 . Known history heparininduced thrombocytopenia . 4 . Contraindication unfractionated heparin , bivalirudin , anticoagulant antithrombotic pharmacological agent . 5 . Any significant medical condition , investigator 's opinion , may interfere patient 's optimal participation study . 6 . Pregnant woman nurse mother .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Stable Angina</keyword>
	<keyword>Percutaneous Coronary Intervention</keyword>
</DOC>